Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled nitric oxide for treatment of COVID-19
RBR-8nfx26Phase 2Not yet recruiting
- Sponsor
- Pontifical Catholic University of Rio Grande do Sul
- Start
- Jul 2021
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of nitric oxide in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Pontifical Catholic University of Rio Grande do Sul. Planned start Jul 2021; status: not yet recruiting.
02
Drugs
nitric oxide
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on RBR-8nfx26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-8nfx26.